Typhoid is a serious and sometimes fatal disease spread through contaminated food and water that results in more than 7 million cases and more than 93,000 deaths globally each year, mostly in children and young adults in Asia and sub-Saharan Africa. Increasing drug resistance, urbanization, and climate change elevate the urgency for better typhoid prevention and control. But there is good news. We now have typhoid conjugate vaccines (TCV) that provide safe and effective protection against typhoid.
In this webinar, experts share firsthand experiences with TCV introduction and implementation in Bangladesh, Nepal, and Burkina Faso.
- Firdausi Qadri, PhD, MSc, International Centre for Diarrhoeal Disease Research, Bangladesh
- Krishna Prasad Paudel, PhD, Ministry of Health and Population, Nepal
- Sodiomon Bienvenu Sirima, MD, PhD, CEO, Groupe de Recherche Action en Santé (GRAS), Burkina Faso
- Matthew Laurens, MD, MPH, Center for Vaccine Development and Global Health, University of Maryland School of Medicine, and Typhoid Vaccine Acceleration Consortium (TyVAC) director
- Emmanuel Mugisha, PhD, MPH, PATH TyVAC director
Date: April 16
Time: 8 a.m. Eastern Time